Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC Study

Silvia Giovannini, Henriëtte G. van der Roest, Angelo Carfì, Harriet Finne-Soveri, Vjenka Garms-Homolová, Anja Declercq, Pálmi V. Jónsson, Hein van Hout, Davide L. Vetrano, Ester Manes Gravina, Roberto Bernabei, Graziano Onder

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0%) HC patients and excessive polypharmacy in 433 (23.1%). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95% confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95% CI 1.15–1.98), dyspnea (OR 1.37; 95% CI 1.01–1.89), and falls (OR 1.55; 95% CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95% CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.

Original languageEnglish
Pages (from-to)145-152
Number of pages8
JournalDrugs and Aging
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Polypharmacy
Home Care Services
Odds Ratio
Confidence Intervals
Pharmaceutical Preparations
Cross-Sectional Studies
Benchmarking
Sex Ratio
Practice Guidelines
Dyspnea
Comorbidity

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this

Giovannini, S., van der Roest, H. G., Carfì, A., Finne-Soveri, H., Garms-Homolová, V., Declercq, A., ... Onder, G. (2018). Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC Study. Drugs and Aging, 35(2), 145-152. https://doi.org/10.1007/s40266-018-0521-y

Polypharmacy in Home Care in Europe : Cross-Sectional Data from the IBenC Study. / Giovannini, Silvia; van der Roest, Henriëtte G.; Carfì, Angelo; Finne-Soveri, Harriet; Garms-Homolová, Vjenka; Declercq, Anja; Jónsson, Pálmi V.; van Hout, Hein; Vetrano, Davide L.; Gravina, Ester Manes; Bernabei, Roberto; Onder, Graziano.

In: Drugs and Aging, Vol. 35, No. 2, 01.02.2018, p. 145-152.

Research output: Contribution to journalArticle

Giovannini, S, van der Roest, HG, Carfì, A, Finne-Soveri, H, Garms-Homolová, V, Declercq, A, Jónsson, PV, van Hout, H, Vetrano, DL, Gravina, EM, Bernabei, R & Onder, G 2018, 'Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC Study', Drugs and Aging, vol. 35, no. 2, pp. 145-152. https://doi.org/10.1007/s40266-018-0521-y
Giovannini S, van der Roest HG, Carfì A, Finne-Soveri H, Garms-Homolová V, Declercq A et al. Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC Study. Drugs and Aging. 2018 Feb 1;35(2):145-152. https://doi.org/10.1007/s40266-018-0521-y
Giovannini, Silvia ; van der Roest, Henriëtte G. ; Carfì, Angelo ; Finne-Soveri, Harriet ; Garms-Homolová, Vjenka ; Declercq, Anja ; Jónsson, Pálmi V. ; van Hout, Hein ; Vetrano, Davide L. ; Gravina, Ester Manes ; Bernabei, Roberto ; Onder, Graziano. / Polypharmacy in Home Care in Europe : Cross-Sectional Data from the IBenC Study. In: Drugs and Aging. 2018 ; Vol. 35, No. 2. pp. 145-152.
@article{5332e0ff57634cc8910959ddc3ccf754,
title = "Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC Study",
abstract = "Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0{\%}) HC patients and excessive polypharmacy in 433 (23.1{\%}). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95{\%} confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95{\%} CI 1.15–1.98), dyspnea (OR 1.37; 95{\%} CI 1.01–1.89), and falls (OR 1.55; 95{\%} CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95{\%} CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.",
author = "Silvia Giovannini and {van der Roest}, {Henri{\"e}tte G.} and Angelo Carf{\`i} and Harriet Finne-Soveri and Vjenka Garms-Homolov{\'a} and Anja Declercq and J{\'o}nsson, {P{\'a}lmi V.} and {van Hout}, Hein and Vetrano, {Davide L.} and Gravina, {Ester Manes} and Roberto Bernabei and Graziano Onder",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s40266-018-0521-y",
language = "English",
volume = "35",
pages = "145--152",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Springer International Publishing",
number = "2",

}

TY - JOUR

T1 - Polypharmacy in Home Care in Europe

T2 - Cross-Sectional Data from the IBenC Study

AU - Giovannini, Silvia

AU - van der Roest, Henriëtte G.

AU - Carfì, Angelo

AU - Finne-Soveri, Harriet

AU - Garms-Homolová, Vjenka

AU - Declercq, Anja

AU - Jónsson, Pálmi V.

AU - van Hout, Hein

AU - Vetrano, Davide L.

AU - Gravina, Ester Manes

AU - Bernabei, Roberto

AU - Onder, Graziano

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0%) HC patients and excessive polypharmacy in 433 (23.1%). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95% confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95% CI 1.15–1.98), dyspnea (OR 1.37; 95% CI 1.01–1.89), and falls (OR 1.55; 95% CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95% CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.

AB - Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0%) HC patients and excessive polypharmacy in 433 (23.1%). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95% confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95% CI 1.15–1.98), dyspnea (OR 1.37; 95% CI 1.01–1.89), and falls (OR 1.55; 95% CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95% CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.

UR - http://www.scopus.com/inward/record.url?scp=85041617509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041617509&partnerID=8YFLogxK

U2 - 10.1007/s40266-018-0521-y

DO - 10.1007/s40266-018-0521-y

M3 - Article

C2 - 29411310

AN - SCOPUS:85041617509

VL - 35

SP - 145

EP - 152

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 2

ER -